Vor Biopharma Inc (VOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vor Biopharma Inc (VOR) has a cash flow conversion efficiency ratio of 0.128x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.67 Million) by net assets ($-200.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Vor Biopharma Inc for the company's overall valuation and market capitalisation.
Vor Biopharma Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Vor Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vor Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vor Biopharma Inc ranked by their cash flow conversion efficiency. Explore VOR cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Yuchai International Limited
NYSE:CYD
|
N/A |
|
Aptus Value Housing Finance India Limited
NSE:APTUS
|
-0.025x |
|
Cpi Fim SA
WAR:OPG
|
0.001x |
|
Alphamin Res
V:AFM
|
0.124x |
|
Suzhou Victory Precision Manufacture Co Ltd
SHE:002426
|
0.002x |
|
Stanley Fertilizer Co Ltd
SHE:002588
|
0.125x |
|
Taiwan FamilyMart Co Ltd
TWO:5903
|
0.445x |
|
Max Stock Ltd
TA:MAXO
|
0.191x |
Annual Cash Flow Conversion Efficiency for Vor Biopharma Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Vor Biopharma Inc from 2018 to 2025. View Vor Biopharma Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-164.31 Million | $-142.71 Million | 0.869x | +184.24% |
| 2024-12-31 | $96.66 Million | $-99.66 Million | -1.031x | -54.94% |
| 2023-12-31 | $150.72 Million | $-100.29 Million | -0.665x | -95.85% |
| 2022-12-31 | $250.61 Million | $-85.14 Million | -0.340x | -6.26% |
| 2021-12-31 | $216.26 Million | $-69.14 Million | -0.320x | +57.47% |
| 2020-12-31 | $48.27 Million | $-36.29 Million | -0.752x | +41.71% |
| 2019-12-31 | $7.64 Million | $-9.86 Million | -1.290x | -428.03% |
| 2018-12-31 | $-6.77 Million | $-2.66 Million | 0.393x | -- |
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with Re… Read more